DIADIA0.80%
SPYSPY1.56%
QQQQQQ2.55%
Trending
Top trending tickerBULLBULL0.36%
QQQQQQ2.55%
SPYSPY1.56%
MUMU11.41%
ASTSASTS14.38%
BABA3.58%
WMTWMT6.07%
SOXLSOXL14.26%
APLDAPLD10.16%
BTCBTC2.93%
Top trending tickerBULLBULL0.36%
QQQQQQ2.55%
SPYSPY1.56%
MUMU11.41%
ASTSASTS14.38%
BABA3.58%
WMTWMT6.07%
SOXLSOXL14.26%
APLDAPLD10.16%
BTCBTC2.93%
homeSymbolGLMD

GLMD
Galmed Pharmaceuticals Ltd

7,590
Mkt Cap
$5.16M
Volume
962,255.00
52W High
$3.61
52W Low
$0.94
PE Ratio
-0.17
GLMD Fundamentals
Price
$0.8149
Prev Close
$0.9422
Open
$0.901
50D MA
$1.37
Beta
1.21
Avg. Volume
78,060.57
EPS (Annual)
-$8.08
P/B
0.24
Rev/Employee
$0.00
Loading...
Loading...

Feed

News

Sentiment

Fundamentals

Info

News
all
press releases
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks
Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.
Stocktwits·3d ago
News Placeholder
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...
PR Newswire·3d ago
News Placeholder
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...
PR Newswire·3mo ago
News Placeholder
Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’
The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.
Stocktwits·7mo ago
News Placeholder
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology PR Newswire TEL AVIV, Israel, Sept. 25, 2024...
PR Newswire·1y ago
News Placeholder
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases PR Newswire...
PR Newswire·1y ago
News Placeholder
Galmed Pharmaceuticals Reports Mid-Year Loss
Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024...
TipRanks Financial Blog·1y ago
News Placeholder
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...
PR Newswire·2y ago
News Placeholder
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)
StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the...
Ticker Report·2y ago

Latest GLMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.